Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan, Steven D; Lancaster, Lisa H; Albera, Carlo; Glassberg, Marilyn K; Swigris, Jeffrey J; Gilberg, Frank; Kirchgaessler, Klaus-Uwe; Limb, Susan L; Petzinger, Ute; Noble, Paul W

Nathan, Steven D; Lancaster, Lisa H; Albera, Carlo; Glassberg, Marilyn K; Swigris, Jeffrey J; Gilberg, Frank; Kirchgaessler, Klaus-Uwe; Limb, Susan L; Petzinger, Ute; Noble, Paul W.

Affiliation

Nathan SD; Inova Fairfax Hospital, Falls Church, Virginia, USA.
Lancaster LH; Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Albera C; University of Turin, Orbassano, Turin, Italy.
Glassberg MK; Miller School of Medicine, University of Miami, Miami, Florida, USA.
Swigris JJ; Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado, USA.
Gilberg F; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Kirchgaessler KU; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Limb SL; Genentech, South San Francisco, California, USA.
Petzinger U; Accovion, Eschborn, Hessen, Germany.
Noble PW; Cedars-Sinai Medical Center, Los Angeles, California, USA.

BMJ Open Respir Res ; 5(1): e000323, 2018.

Article in En | MEDLINE | ID: mdl-30116539

Key words

interstitial fibrosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: BMJ Open Respir Res Year: 2018 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google